Log In
Print
BCIQ
Print
Print this Print this
 

ublituximab (LFB-R603, TG-1101, TGTX-1101)

  Manage Alerts
Collapse Summary General Information
Company LFB S.A.
DescriptionGlycoengineered mAb against CD20
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$2.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today